

Our competitive advantages

We are positioned for success ...

1 With our proprietary technologies

- Our patent estate consists of over 40 patents worldwide covering our cell-based therapies, exosome and iPSCs technologies.
- A highly efficient, patented process is used to produce hRPCs on a large scale.
- Our CTX drug product is a proprietary allogeneic cell therapy produced by our well-established, scalable manufacturing process. (Allogeneic: recipients of cells are immunologically different from cell donor.)
- Our high-yielding human neural stem cell derived exosomes have proven ability to be loaded with siRNA, miRNA and proteins, and are able to cross the Blood Brain Barrier.
- Our iPSC platform technology engineers CTX neural stem cells into other forms of stem cell.

2 With our flexible cryopreservation process

- Our hRPCs and CTX cells can be cryopreserved, which provides flexibility in terms of scheduling patient treatment.
- This makes our product similar to conventional 'off-the-shelf' pharmaceuticals/biologics.
- Our cryopreservation process allows us to develop the therapies and transport them globally.

3 With our efficient development pipeline

- Our therapy development pipeline spans the pre-clinical and clinical development process.
- We have seen positive top-line efficacy data presented from Phase 2a patients in ongoing US Phase 1/2a clinical trial in retinitis pigmentosa. The ongoing Phase 2a study is to be expanded to allow for subsequent potential single pivotal clinical study and shorter route to market.
- There are significant clinical validation milestones due in the next 18 months in our ongoing clinical trial in retinitis pigmentosa.
- The exosomes we are harnessing for use are a by-product of our CTX cells and are derived from a GMP compliant process. They can be produced at an industrial scale without affecting the quality and consistency of the final product. They have potential as both a drug load/delivery vehicle and as a therapeutic.
- Our iPSC platform has potential for new targeted cell therapeutics and for exosomes based on non neural stem cells.